Clinical Trial Update: PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluating intratumoral microdosing of pembrolizumab alone or with MK-0482 or MK-4830 in head and neck squamous cell carcinoma or soft tiss…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Soft Tissue Sarcoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• MK-0482
• MK-4830 (MK-4830)

Snippet

Sponsor: Presage Biosciences | Conditions: Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma | EARLY_Phase 1 | Status: COMPLETED